Trinity Biotech

Trinity Biotech Current Assets

The Current Assets of Trinity Biotech (TRIB) as of Nov 11, 2026 is 25.62 M USD. In the previous year, Current Assets was 41.12 M USD — a change of -37.70% (lower).

Current Assets

25.62 MUSD

YoY

-37.70%

Last updated:

Current Assets of Trinity Biotech is 2025 25.62 M USD. Current Assets of Trinity Biotech was 2024 41.12 M USD. It decreases by -37.70% lower compared to the previous year.

The Trinity Biotech Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
112.69 M USD
Jan 1, 2019
93.78 M USD
Jan 1, 2020
83.30 M USD
Jan 1, 2021
72.69 M USD
Jan 1, 2022
46.67 M USD
Jan 1, 2023
38.67 M USD
Jan 1, 2024
41.12 M USD
Jan 1, 2025
25.62 M USD
The Trinity Biotech Current Assets history
YEARCurrent AssetsYoY
25.62 MUSD-37.70%
41.12 MUSD+6.35%
38.67 MUSD-17.14%
46.67 MUSD-35.80%
72.69 MUSD-12.74%
83.30 MUSD-11.18%
93.78 MUSD-16.77%
112.69 MUSD+38.19%
81.55 MUSD-40.53%
137.12 MUSD-15.99%
163.23 MUSD+121.18%
73.80 MUSD-7.58%
79.85 MUSD-28.52%
111.71 MUSD-4.05%
116.43 MUSD+14.91%
101.32 MUSD+48.27%
68.34 MUSD-9.08%
75.17 MUSD-5.77%
79.77 MUSD-20.57%
100.43 MUSD+27.27%
78.91 MUSD+1.09%
78.06 MUSD+47.38%
52.96 MUSD+103.47%
26.03 MUSD+10.38%
23.58 MUSD-11.69%
26.70 MUSD+35.09%
19.77 MUSD+12.64%
17.55 MUSD+40.31%
12.51 MUSD+101.74%
6.20 MUSD-20.51%
7.80 MUSD+680.00%
1.00 MUSD-47.37%
1.90 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Current Assets of Trinity Biotech is 25.62 M USD in 2025.

Current Assets of Trinity Biotech changed from 41.12 M USD to 25.62 M USD, representing a -37.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Trinity Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Trinity Biotech

All Key Metrics — Trinity Biotech